Ratings Bumrungrad Hospital

Equities

BH

TH0168A10Z01

End-of-day quote Thailand S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
248 ^THB	-1.98%		+10.71%	+11.71%

Apr. 25	Bumrungrad Hospital Public Company Limited Approves Dividend for an Operating Period from 1 July 2023 to 31 December 2023, Payable on 10 May 2024	CI
Apr. 25	Bumrungrad Hospital Public Company Limited Elects Chanida Sophonpanich as Non-Executive Director	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
With an expected P/E ratio at 28.26 and 26.72 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
BUMRUNGRAD HOSPITAL	+11.71%	5.43B		B
CVS HEALTH CORPORATION	-15.03%	84.87B		B-
HCA HEALTHCARE, INC.	+10.42%	83.08B		C+
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.4B		C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-12.55%	16.72B		B
FRESENIUS SE & CO. KGAA	-3.06%	16.4B		A-
QUEST DIAGNOSTICS INCORPORATED	-1.86%	15.04B		A-
EUROFINS SCIENTIFIC SE	-3.97%	11.88B		A-
FRESENIUS MEDICAL CARE AG	-1.42%	11.88B		A-
PURE HEALTH HOLDING	-31.75%	11.86B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes